SEC Tracker
Get the app

Alto Neuroscience ANRO

Alto Neuroscience reports Q3 2026 financial results

Alto Neuroscience (ANRO) filed an 8-K with the SEC on Nov 10, 2026, 4:13 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash position of $319.8 million as of September 30, 2026
  2. R&D expenses increased to $18.2 million in Q3 2026
  3. PACE-1 trial of Alto-207 expected to deliver topline data in 2H 2027
  4. Company extended cash runway to 2030 with $100 million financing

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Alto Neuroscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.